Radioligand Therapy (RLT)

A targeting molecule that delivers a radioactive payload to kill tumors from within.

Radioligand therapy borrows the ADC idea but swaps the chemo warhead for a radioactive isotope. A small targeting molecule seeks a protein on the tumour surface (PSMA in prostate cancer, SSTR in neuroendocrine tumours); a chemical cage called a chelator clamps the isotope to it. Once docked, the isotope emits radiation that destroys the cancer over a few cell-diameters.

The elegant part is theranostics: pair the same ligand with an imaging isotope and you can see exactly which patients will respond before you treat them. It's one of oncology's fastest-growing modalities — and it runs on a specialist radioisotope supply chain.

How it works in depth

A radioligand therapy pairs two parts: a targeting ligand (a small molecule, peptide, or antibody fragment that binds a protein over-expressed on tumor cells) and a radioactive isotope joined through a chelator and linker. After infusion, the ligand circulates and docks onto its target, concentrating the radiation at the tumor while sparing most healthy tissue. The payload then emits ionizing radiation that breaks DNA and kills the cell.

Most approved agents use the beta-emitter lutetium-177, which deposits energy over roughly a millimeter and benefits from a useful 'crossfire' effect on neighboring cells. Newer programs chase alpha-emitters such as actinium-225, whose much shorter range and far higher energy can be more lethal per decay, potentially overcoming beta resistance. A practical advantage is the theranostic pairing: swapping the therapeutic isotope for an imaging one (for example gallium-68 PSMA PET) lets clinicians confirm target expression and select patients before treating.

Where the field is in 2025-2026

RLT has moved from niche to mainstream oncology. Novartis' two anchor products posted strong 2025 revenue, with Pluvicto (lutetium-177 PSMA-617, prostate cancer) reportedly around USD 1.9 billion and Lutathera (lutetium-177 dotatate, neuroendocrine tumors) near USD 816 million. In March 2026 the FDA expanded Pluvicto's label to a pre-chemotherapy setting in PSMA-positive metastatic castration-resistant prostate cancer, and Novartis reported a radiographic progression-free survival benefit in the earlier-line PSMAddition trial (overall survival immature as of 2025). One market estimate sees the sector growing from about USD 2.6 billion in 2025 to USD 4.8 billion by 2030. The dominant bottleneck is isotope supply: actinium-225 production reportedly sits far below projected demand, spurring capacity efforts from the US DOE Tri-Lab program, TerraPower, NorthStar, BWXT and others.

Leading programs & players

Big pharma has consolidated aggressively. Novartis leads commercially. Bristol Myers Squibb acquired RayzeBio (~USD 4.1B, 2024) for actinium-based RYZ101. Eli Lilly bought Point Biopharma (~USD 1.4B, closed 2023), and AstraZeneca acquired Fusion Pharmaceuticals (~USD 2.4B, 2024). Privately held ITM awaits an FDA decision on ITM-11 (lutetium-177 edotreotide) in neuroendocrine tumors, with a reported goal date of August 28, 2026. Key debates center on alpha versus beta emitters, optimal dosing and number of cycles, sequencing against chemotherapy, and whether isotope and manufacturing logistics can scale to meet demand.

FAQ

What cancers is radioligand therapy used for?

Approved RLTs treat PSMA-positive metastatic castration-resistant prostate cancer (Pluvicto) and somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors (Lutathera). Many trials are testing it in additional solid tumors.

What is the difference between Pluvicto and Lutathera?

Both use lutetium-177. Pluvicto (lutetium-177 PSMA-617) targets PSMA on prostate cancer cells, while Lutathera (lutetium-177 dotatate) targets somatostatin receptors on neuroendocrine tumors. Both are marketed by Novartis.

What is the difference between alpha and beta radioligand therapy?

Beta emitters like lutetium-177 travel about a millimeter and treat clusters of cells via crossfire. Alpha emitters like actinium-225 have a very short range but deposit much higher energy, which may be more potent but requires precise targeting and scarce isotope supply.

Why is actinium-225 supply a problem?

Actinium-225 is difficult to produce, and reported global supply is far below projected demand as pipelines expand. Programs from the US DOE Tri-Lab effort, TerraPower, NorthStar and others are racing to add manufacturing capacity.

Companies working on Radioligand Therapy (RLT)

Explore the interactive landscapes →